vs

Side-by-side financial comparison of Citi Trends Inc (CTRN) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $197.1M, roughly 1.6× Citi Trends Inc). Citi Trends Inc runs the higher net margin — -3.5% vs -18.2%, a 14.7% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 10.1%). Citi Trends Inc produced more free cash flow last quarter ($767.0K vs $-133.8M).

Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

CTRN vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.6× larger
MDGL
$321.1M
$197.1M
CTRN
Growing faster (revenue YoY)
MDGL
MDGL
+200.7% gap
MDGL
210.8%
10.1%
CTRN
Higher net margin
CTRN
CTRN
14.7% more per $
CTRN
-3.5%
-18.2%
MDGL
More free cash flow
CTRN
CTRN
$134.6M more FCF
CTRN
$767.0K
$-133.8M
MDGL

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CTRN
CTRN
MDGL
MDGL
Revenue
$197.1M
$321.1M
Net Profit
$-6.9M
$-58.6M
Gross Margin
Operating Margin
-3.7%
-18.6%
Net Margin
-3.5%
-18.2%
Revenue YoY
10.1%
210.8%
Net Profit YoY
3.6%
1.4%
EPS (diluted)
$-0.86
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRN
CTRN
MDGL
MDGL
Q4 25
$197.1M
$321.1M
Q3 25
$190.8M
$287.3M
Q2 25
$201.7M
$212.8M
Q1 25
$211.2M
$137.3M
Q4 24
$179.1M
$103.3M
Q3 24
$176.6M
$62.2M
Q2 24
$186.3M
Q1 24
$215.2M
$0
Net Profit
CTRN
CTRN
MDGL
MDGL
Q4 25
$-6.9M
$-58.6M
Q3 25
$3.8M
$-114.2M
Q2 25
$871.0K
$-42.3M
Q1 25
$-14.2M
$-73.2M
Q4 24
$-7.2M
$-59.4M
Q3 24
$-18.4M
$-107.0M
Q2 24
$-3.4M
Q1 24
$3.6M
$-147.5M
Gross Margin
CTRN
CTRN
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CTRN
CTRN
MDGL
MDGL
Q4 25
-3.7%
-18.6%
Q3 25
1.8%
-39.7%
Q2 25
0.2%
-22.2%
Q1 25
0.6%
-57.8%
Q4 24
-4.9%
-64.8%
Q3 24
-14.1%
-187.1%
Q2 24
-3.7%
Q1 24
1.8%
Net Margin
CTRN
CTRN
MDGL
MDGL
Q4 25
-3.5%
-18.2%
Q3 25
2.0%
-39.8%
Q2 25
0.4%
-19.9%
Q1 25
-6.7%
-53.4%
Q4 24
-4.0%
-57.5%
Q3 24
-10.4%
-172.0%
Q2 24
-1.8%
Q1 24
1.7%
EPS (diluted)
CTRN
CTRN
MDGL
MDGL
Q4 25
$-0.86
$-2.55
Q3 25
$0.46
$-5.08
Q2 25
$0.11
$-1.90
Q1 25
$-1.70
$-3.32
Q4 24
$-0.86
$-2.50
Q3 24
$-2.21
$-4.92
Q2 24
$-0.42
Q1 24
$0.43
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRN
CTRN
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$107.8M
$602.7M
Total Assets
$464.3M
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRN
CTRN
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Q1 24
$622.5M
Total Debt
CTRN
CTRN
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
CTRN
CTRN
MDGL
MDGL
Q4 25
$107.8M
$602.7M
Q3 25
$113.2M
$625.7M
Q2 25
$108.6M
$696.0M
Q1 25
$113.2M
$710.6M
Q4 24
$130.3M
$754.4M
Q3 24
$136.6M
$777.2M
Q2 24
$154.8M
Q1 24
$157.7M
$850.8M
Total Assets
CTRN
CTRN
MDGL
MDGL
Q4 25
$464.3M
$1.3B
Q3 25
$457.4M
$1.4B
Q2 25
$437.4M
$1.0B
Q1 25
$462.8M
$996.6M
Q4 24
$467.1M
$1.0B
Q3 24
$506.7M
$1.1B
Q2 24
$484.1M
Q1 24
$518.7M
$1.1B
Debt / Equity
CTRN
CTRN
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRN
CTRN
MDGL
MDGL
Operating Cash FlowLast quarter
$8.6M
$-133.5M
Free Cash FlowOCF − Capex
$767.0K
$-133.8M
FCF MarginFCF / Revenue
0.4%
-41.7%
Capex IntensityCapex / Revenue
4.0%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$11.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRN
CTRN
MDGL
MDGL
Q4 25
$8.6M
$-133.5M
Q3 25
$3.9M
$79.8M
Q2 25
$-11.0M
$-47.1M
Q1 25
$28.5M
$-88.9M
Q4 24
$-18.4M
$-104.5M
Q3 24
$5.6M
$-67.0M
Q2 24
$-19.6M
Q1 24
$23.3M
$-149.2M
Free Cash Flow
CTRN
CTRN
MDGL
MDGL
Q4 25
$767.0K
$-133.8M
Q3 25
$-1.7M
$79.0M
Q2 25
$-13.1M
Q1 25
$26.0M
Q4 24
$-20.4M
$-104.7M
Q3 24
$1.7M
$-67.8M
Q2 24
$-21.2M
Q1 24
$20.0M
$-149.5M
FCF Margin
CTRN
CTRN
MDGL
MDGL
Q4 25
0.4%
-41.7%
Q3 25
-0.9%
27.5%
Q2 25
-6.5%
Q1 25
12.3%
Q4 24
-11.4%
-101.3%
Q3 24
0.9%
-109.0%
Q2 24
-11.4%
Q1 24
9.3%
Capex Intensity
CTRN
CTRN
MDGL
MDGL
Q4 25
4.0%
0.1%
Q3 25
2.9%
0.3%
Q2 25
1.0%
0.0%
Q1 25
1.2%
0.0%
Q4 24
1.1%
0.2%
Q3 24
2.2%
1.3%
Q2 24
0.9%
Q1 24
1.5%
Cash Conversion
CTRN
CTRN
MDGL
MDGL
Q4 25
Q3 25
1.01×
Q2 25
-12.59×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
6.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTRN
CTRN

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons